BioVaxys Technology Corp. C.BIOV

With this group you never know what/when news will be

[frankman]

Executive Team & Board
of Directors

 

James Passin

Founder, Chief Executive Officer and Director

Mr. James Passin is a former hedge fund and private equity fund manager at FGS Advisors, LLC, an affiliate of New York-based  Firebird  Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies,  Inc., one of the world’s  first cellular immunotherapeutic vaccine  companies. He is a director of  several public companies, including TraceSafe Inc. (CSE: TSF) and BDSec JSC  (MSE: BDS), is a Chartered Market Technician and member of the CMT Association.. 

 

Kenneth Kovan

Founder, President and Chief Operating Officer

Mr. Kovan has over 30 years of experience in biopharmaceuticals commercial development. He recently served as Corporate Development Partner with Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012 that specializes in corporate development, technology licensing, and business planning. He is an experienced former biotech CEO and board member, and founder of biotechnology companies including the former Avax Technologies, Inc. Mr. Kovan’s professional background includes several years in technology transfer with Thomas Jefferson University, Strategic Marketing with GlaxoSmithKline, and Global New Product Development with Wyeth-Ayerst Pharmaceuticals. His therapeutic experience includes infectious disease, antivirals, oncology, vaccines, cell/gene therapy, and gene editing. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets, and has worked in Europe for several years.

 

David Berd, M.D.

Founder and Chief Medical Officer

Dr. David Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He cofounded cancer immunotherapy company AVAX Technologies, is the inventor of the cancer vaccines MVax™ and OVax™, and served as Chief Medical Officer 2005-2008. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. He has ten issued patents dealing with cancer vaccines. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.

 

Lachlan McLeod, CPA

Chief Financial Officer

Mr. Lachlan McLeod, a Chartered Professional Accountant, holds a Bachelor’s Degree in Science with an Economics major and a Business minor from the University of Victoria. He has 6 years of experience focusing on financial reporting under IFRS, governance for public companies, and technical accounting issues, including work as an auditor at KPMG. Mr. McLeod currently works as a Senior Consultant at Fehr & Associates CPA, which provides external consulting and accounting services.

[ando]

Incredibly strong team. I see it as one day we wake up and the shares are worth 4X What they were the day before

[edjohnson]

FDA approvals do that. there is no limit here. PASSINAND SHMUEL 2021. LOOK OUT $$$

[ando]

100% I call it, these will look like ity bity blips in the chart in 3-5 years when its trading in dollars. STRONG TEAM and shareholder base

[bomdrou99]

At 3:59 p.m., TD Bank customer (s) bought 82,500 shares at 0.57, the highest price of the day. Expect a significant rise in the share price on Monday. I believe there will be more great news in the future very soon.

[ando]

Wow. 1 buyer buying that much at market definitely knows something. The future for this company is almost unthinkable. COVID & CANCER answers is wild. Glad to be along for the ride. Ando